MedTrace Logo

Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa

NCT04982432 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-09-28

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of oral administration of orismilast for treatment of mild, moderate, or severe hidradenitis suppurativa (HS) in adults.

Conditions

Interventions

DRUG

Orismilast

Orismilast is a next generation PD4 inhibitor with demonstrated broad anti inflammatory properties

Sponsors & Collaborators

  • UNION therapeutics

    collaborator INDUSTRY

  • Gregor Jemec

    lead OTHER

Principal Investigators

  • Gregor Jemec, Professor · Zealand University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2022-12-01
Completion
2022-12-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04982432 on ClinicalTrials.gov